Background Heparin needs the plasma protein antithrombin III to function as an inhibitor of thrombin, and local antithrombin III deficiency might therefore limit the antithrombotic effectiveness of heparin during percutaneous transluminal coronary angioplasty.
Methods and Results In the present double-blind study, 615 consecutive patients undergoing percutaneous transluminal coronary angioplasty (PTCA), of a total of 713 stenoses, were prospectively randomized to receive a bolus injection of 15 000 U heparin followed by a continuous intracoronary infusion via the guiding catheter of either 250 U heparin per minute or 250 U heparin plus 25 U antithrombin III per minute during the procedure. Four clinical variables, 19 lesion-specific characteristics, and 16 procedure-related variables were evaluated. Procedural success was assessed by quantitative angiography; procedure-related ischemic complications were analyzed during in-hospital follow-up. Procedural success rates (<50% final diameter stenosis and no major ischemic complication) were similar, with 85% in the heparin group (n=324 patients) and 83% in the heparin+antithrombin III group (n=291 patients).
Percent diameter stenosis after PTCA was 39±18% in the heparin group and 40±20% in the heparin+antithrombin III P z eriprocedural occlusion has remained the most serious complication of percutaneous transluminal coronary angioplasty (PTCA). PTCA-related acute closure not only is associated with an increased risk of in-hospital myocardial infarction, emergency coronary artery bypass graft surgery, and death'-3 but also may lead to an excess mortality after hospital discharge. 4 Although advances in catheter technology and increased operator experience have allowed a rapid growth in apparent indications and in the application of PTCA,5 the incidence of periprocedural occlusion has remained constant over time.46-8 Coronary artery dissection and acute thrombosis are the predominant causes of PTCArelated acute vessel occlusion3,4,8-'0; at least half of these acute closure events are due to coronary artery thrombosis, and the others may be related to vessel wall group (NS). There were no differences between the two groups with respect to PTCA-related acute vessel occlusion, angiographic evidence of intracoronary thrombus formation, postprocedure creatine kinase increase, Q-wave myocardial infarction, or emergency coronary artery bypass surgery. High-risk subgroup analysis revealed no beneficial effect of adjunctive intracoronary antithrombin III in any of the analyzed subgroups. In addition, although risk stratification according to the criteria of the American College of Cardiology/American Heart Association Task Force classification proved to be very useful for the entire study population, no beneficial effect of intracoronary antithrombin III PTCA.12 Therefore, the present double-blind, randomized study was designed to determine whether an adjunctive intracoronary infusion of antithrombin III does have any beneficial effect compared with heparin alone with respect to the procedural success rates and the frequency and type of acute complications in patients undergoing PTCA. 1992 were enrolled in this prospective, randomized trial. Excluded from the study were patients who had an evolving myocardial infarction.
Study Design
All patients were pretreated with oral aspirin (100 to 325 mg/d). After insertion of the arterial sheath into the femoral artery, all patients received 15 000 U heparin via the sheath and usually 0.2 to 0.3 mg nitroglycerin into the coronary system via the guiding catheter after the coronary arterial ostium was engaged. The patients were then randomized to receive a continuous intracoronary infusion of either 250 U heparin per minute or 250 U heparin plus 25 U antithrombin III (Behring Werke) via the guiding catheter at an infusion rate of 2 mL/min. The operators were blinded as to treatment assignment during the entire phase of the procedure, film analysis, and data entry.
The size of the study population was designed to detect a reduction in the incidence of intracoronary thrombus formation, the major risk factor for PTCA-related acute occlusion, from 12%13 to 6% with a predictive power of >90% (P<.05 by two-tailed test).
Angioplasty Procedure
Procedures were performed by the Judkins technique with steerable balloon catheters. Coronary angiography was performed using simultaneous biplane multidirectional x-ray systems at a frame rate of 12.5 frames per second. The artery to be dilated was positioned near the isocenter, and a number of preliminary angiograms were recorded to obtain two, whenever possible orthogonal, simultaneous projections best showing the stenosis and the adjacent artery segments. The projections were then kept constant throughout the procedure. Balloon sizes were chosen to approximate the diameter of the "normal" coronary segment adjacent to the site to be dilated. The balloon was positioned across the stenosis and inflated as many times as necessary to produce an adequate result according to angiographic criteria. After an observation period of 10 minutes after the final balloon inflation, all catheters were removed, but the femoral sheaths were left in place. Sheaths were usually removed 3 to 4 hours later unless there was angiographic evidence of an extensive coronary arterial dissection or large amounts of thrombus, in which case the sheaths were left in place overnight. Except for aspirin, no specific medication was routinely given after the procedure, and the patients were monitored on a postprocedure ward for 18 to 
Procedural Variables
The procedural variables included procedure time, defined as the time span from the very first moment the guide wire entered the coronary system until the guiding catheter was removed; guide wire passage time, defined as the time needed to cross the lesion with the guide wire; number of balloon inflations, defined as the total number of balloon inflations during a procedure; total duration of balloon inflation, defined as the added time of all balloon inflations during a procedure; maximum inflation pressure, defined as the maximum inflation pressure applied during the procedure; balloon size, defined as maximum balloon size used during the procedure; intimal tear or dissection, defined as a curvilinear intraluminal filling defect or widening with contrast staining at the site of dilation after PTCA; thrombus formation, defined as formation of an intraluminal filling defect, either largely separated from the vessel wall at the site of balloon dilation or adherent to the intracoronary guide wire as evidenced by back and forward movement of the guide wire under fluoroscopic control; multilesion PTCA, defined as two or more stenoses dilated in one of the major three coronary arteries; and multivessel PTCA, defined as at least two stenoses dilated in two or all three major coronary arteries.
Procedural Outcome
Procedural success was defined as a reduction in diameter stenosis (mean value of two simultaneous, usually orthogonal projections) of all attempted lesions to <50% without any major ischemic complications, including death, coronary artery bypass graft surgery, or myocardial infarction (new Q waves or cardiac enzyme elevation with or without ischemic symptoms) during hospitalization.
Procedure-related complications included death resulting from attempted PTCA; coronary artery bypass graft surgery during hospitalization; myocardial infarction: development of new Q waves in the ECG (12-lead) with elevation of cardiac enzymes resulting from procedure-induced ischemia; acute vessel occlusion, TIMI flow grade 0 to 1, during the procedure or at any time during hospitalization after attempted PTCA; and postprocedure increases in creatine kinase > 140 U/L with a significant MB fraction.
Management of Acute Coronary Artery Occlusion
Acute vessel closure was managed on an individual basis at the operator's discretion. In general, however, the following strategy was applied: bolus injection of intracoronary nitroglycerin followed by redilatation of the area of occlusion with a normal-size balloon; if unsuccessful, a longer duration of balloon inflation was attempted with an "oversized" balloon. The characteristics of the study population and of the stenoses dilated and the procedure-related variables are summarized in Tables 2, 3 , and 4, respectively. There were no differences in any of the variables between the patients receiving heparin alone (heparin group) and the patients receiving heparin plus antithrombin III (AT-III group). Of importance, 41% of the patients had unstable angina, and 43% of these patients (18% of the 
Procedural Outcome
Of all attempted lesions, 84.3% (601 of 713) were successfully dilated without major ischemic complications. Fig 1, illustrating the cumulative distribution of the lesions before and after PTCA, demonstrates that the curves were essentially superimposed for both groups before and after PTCA, indicating that there were no differences between the heparin group and the AT-Ill group. Overall procedural success rates were 83% in the AT-Ill group and 85% in the heparin group. Mean stenosis severity after PTCA was 40±20% in the AT-Ill group and 39±18% in the heparin group (NS versus AT-Ill group). Antithrombin III Effects in High-Risk Subgroups For the entire study population, increasing stenosis complexity (according to the modified ACC/AHA classification scheme) was associated with a significant decrease in procedural success (type A, 94%; B1, 89%; B2, 87%; C, 69%; P<.001) and a significant increase in acute procedure-related occlusion (type A, 1.8%; B1, 2.5%; B2, 9.0%; C, 6.3%; P<.05) . Fig 2 illustrates that the adjunctive intracoronary infusion of antithrombin III had no demonstrable beneficial effect on procedural success rates or procedure-related occlusion even in high-risk subgroups.
Procedural success rates were similar in patients with stable angina (84%) and unstable angina (85%) regardless of the adjunctive administration of antithrombin III. Within the group of patients with unstable angina, patients with crescendo angina (n= 130) had a tendency toward a lower procedural success rate, 81%, compared with patients with acute coronary insufficiency syndromes (n= 148) with a procedural success rate of 88% (P=NS versus crescendo angina). Again, as illustrated in Fig 3, antithrombin III had no demonstrable beneficial effects in the various subgroups.
The frequency of acute procedure-related occlusion in the catheterization laboratory was similar for stable angina (7.2%) and unstable angina (7%), and within the group of patients with unstable angina, those patients with crescendo angina had a tendency toward an increased risk of procedure-related occlusion, with 9.2% compared with those patients with acute coronary insufficiency syndromes (occlusions in the laboratory, 5.4%; P=NS versus crescendo angina). However, antithrombin III did not affect procedure-related occlusion in either group (Fig 3) .
Effects of Antithrombin III on Intracoronary Thrombus Formation
Intracoronary thrombus formation during the procedure is a major risk factor for adverse events during PTCA. In the present study, intracoronary thrombus formation was associated with a marked increase in the incidence of procedure-related vessel occlusion (16.4% versus 6.1%; P<.005). The presence of unstable angina, irregular stenosis morphology, and stenosis complexity have been shown to be predictors of an increased risk of thrombus formation during PTCA. Fig 4 illustrates that antithrombin III did not reduce the incidence of intracoronary thrombus formation in any of these subgroups at risk in the present study.
Discussion
The results of the present study demonstrate that the adjunctive intracoronary infusion of antithrombin III does not affect procedural success rates and frequency of acute complications in patients undergoing PTCA. Even when high-risk subgroups of patients were analyzed separately, no additional benefit of intracoronary antithrombin III compared with heparin alone could be observed. Thus, a local deficiency of antithrombin III does not play a major role for the failure of heparin to abolish thrombotic complications during PTCA. The patient characteristics as well as the angiographic and procedural data were very similar to those of larger recent series assessing predictors of acute complications during PTCA.4,9,15 In addition, both the type and frequency of observed acute complications corresponded closely to those of previously published larger-scale studies.4'16-18 Thus, the study population of the present randomized trial truly reflects the average patient population currently undergoing PTCA. Periprocedural occlusion, the single most important risk factor for inhospital mortality, myocardial infarction, and bypass surgery, occurred in 9.5% of the stenoses, with 72% of occlusions occurring while the patients were still in the cardiac catheterization laboratory and 18% of occlusions occurring outside the catheterization laboratory after initially successful PTCA. Periprocedural occlusion was managed with successful repeat PTCA in 58 of 68 patients (85%), of whom 16 received stent implantation (24%), with emergency coronary bypass surgery in 7.4% (5 patients) and with medical management in the remaining 5 patients (7.4%). These numbers correspond closely to recently reported studies regarding the management of periprocedural occlusions. 4,7'8,16,19,20 The present study indicates that adjunctive therapy with a continuous intracoronary infusion of antithrombin III does not have any apparent beneficial effect on the incidence of periprocedural occlusion, nor Although the present study represents the largest prospective randomized trial of its kind, a limitation of the present study is the number of patients, given the very low overall incidence of acute complications during PTCA. However, since we did not observe any indication that the addition of antithrombin III to heparin may be superior to heparin alone, even in high-risk subgroups, we do not believe that an even larger-scale trial might reveal a beneficial effect of concomitant intracoronary antithrombin III therapy during routine PTCA. In addition, the advent of more potent, specific thrombin inhibitors like hirudin37 or hirulog38 for investigational clinical use appears to offer a theoretically more sound and rational pharmacological approach to prevent PTCA-related acute vessel occlusion.
The dose regimen of antithrombin III was chosen on the basis of experience with antithrombin III substitution for the treatment of disseminated intravascular coagulation.39 Since antithrombin III was directly and continuously infused into the coronary system, the local concentrations at the site of the PTCA-related vessel wall trauma should have been in excess of potential consumption by ongoing thrombus formation.
Another limitation of the present study is that we did not monitor the state of anticoagulation by assessing the activated clotting time in each individual patient during the procedure. However, it has been shown that a dose of 10000 U heparin given at the beginning of the procedure followed by a continuous infusion of 2000 U/h resulted in an acute clotting time within the effective therapeutic range in >95% of patients.40 Thus, our dose regimen of an initial bolus of 15 000 U heparin followed by the continuous intracoronary infusion of 250 U/min accumulating to a mean dose of >22 000 U should have been sufficient to produce an effective state of anticoagulation in most if not all patients. Indeed, measurements of partial thrombin time in 200 patients immediately after the procedure revealed a more than threefold increase in partial thromboplastin time in all patients.
In conclusion, this prospective, randomized study demonstrates that 
